Spinraza’s Patent Cliff: Counting Down to 2025
Buried in Biogen’s 2023 annual report is the linchpin number: $1.76 billion in global net sales for Spinraza, with just over half coming from the US. That single product delivered 17 percent of all company revenue last year, underscoring just how exposed Biogen is to patent loss. Trouble is, Spinraza’s core US patent expires in May 2025. At that moment, the stage is set for generic rivals, payer arm-twisting, and a serious hit to one of Biogen’s last big revenue streams.
Biogen doesn’t trumpet this risk, but it’s there in the fine print, secondary patents exist, for dosing and process, yet those are already under legal assault. If you’ve tracked Copaxone or Humira, you know the drill, “patent thicket” is a delaying tactic, not a permanent moat once the main claim falls. Generics will land, and payers, especially the big pharmacy benefit managers, will force deep discounts as soon as a competitor gets FDA approval.
Consider Copaxone: sales collapsed from $3.1 billion to under $1 billion within three years of US exclusivity loss. Spinraza is arguably more vulnerable. No complex delivery device. Less insulation from commodity pricing. When May 2025 hits, it won’t be gradual attrition, it’ll be a cliff. Not everyone at Biogen is ready for impact, but the numbers don’t lie.
Zolgensma, Evrysdi, and the Race for SMA Market Share
Generics aren’t the whole story. Spinraza is getting squeezed from both ends. On one side, Novartis’s Zolgensma, a one-and-done gene therapy with a breathtaking $2.1 million sticker price, has captured payer deals and significant share in newly diagnosed infants. On the other, Roche’s Evrysdi, launched in 2020, sidestepped Spinraza’s cumbersome spinal injection protocol by offering an oral option. Evrysdi already generates over $800 million in global sales, positioning itself as Spinraza’s main commercial rival.
In response, Biogen talks up long-term outcomes data and leans on its brand, but payers are reshuffling the deck. New SMA formularies increasingly place Spinraza below Evrysdi or enforce step therapy with generics and lower-cost alternatives. PBM updates (see RxPBM.ai) reveal a steady tightening: prior authorizations, restricted uses, and, in some cases, Evrysdi-first requirements. That kind of payer pushback always signals margin trouble ahead.
The pressure’s not theoretical anymore. Since 2021, US net prices for Spinraza are dropping 3 to 5 percent per year. If generic launches trigger price drops even halfway as steep as those seen in MS or RA drugs (where 40-60 percent declines aren’t rare), Spinraza’s US sales risk plunging below $400 million by 2027. That’s not a run-of-the-mill price cut, it’s an existential threat.
Payer Power and the Specialty Pharmacy Squeeze
There was a time when rare disease drugs could bank on sky-high pricing with barely a murmur from payers. Those days are done. Major PBMs, CVS, Cigna, the usual suspects, have already managed to wrest bigger rebates from Biogen late in Spinraza’s lifecycle. Now, they’re preparing SMA for the same aggressive tendering tactics they brought to MS and hepatitis C. Employers aren’t blind to these shifts either.
In the employer benefits channel (RxBenefits.ai), expensive rare disease meds increasingly face caps, carveouts, and value-based deals. Biogen is caught between expiring exclusivity and payer-driven edits, sometimes even mandates to switch to the lowest-cost generic. Not long ago, specialty pharmacy networks couldn’t dictate treatment for rare neurodegenerative disorders. Now, they can, and they do.
Pharmacies feel the pinch too. Margins thin out. Administrative burdens pile up as PBMs demand tighter prior authorizations and lower reimbursements, all in anticipation of generic Spinraza. Expect a spike in prescription savings program activity (RxSaver.ai) as patients and prescribers hustle to limit out-of-pocket costs. Branded Spinraza fades. Volume shifts elsewhere.
Biogen’s Response: The Pivot to Pipeline and Cost Discipline
Biogen’s playbook isn’t exactly revolutionary: highlight the pipeline, tease “next wave” SMA programs, and point to international sales. Doesn’t distract from the math, though. US Spinraza revenue is likely to shrink by $500 million or more, possibly as much as $800 million, within two years. That sort of dent needs more than pipeline teasers and investor optimism.
To stem the bleeding, Biogen is slashing costs, with $1 billion in projected expense cuts by 2025. Sure, that helps. But it doesn’t cover a billion-dollar revenue gap. As soon as generics arrive, specialty pharmacies and PBMs will switch prescriptions. There might be a little breathing room outside the US (certain patents hold until 2027), but Roche and Novartis already have a firm grip there. Biogen’s best-case international scenario amounts to slowing, not reversing, the inevitable.
Let’s be blunt: 2025 will be a watershed for Spinraza’s cash flow. SMA is now a battleground for payers, not a safe haven for easy profits. For Biogen, this isn’t just a single-product headache, it’s a test case for whether rare disease pricing survives the end of exclusivity. Keep an eye on PBM contract structures (RxPBM.ai) and formulary moves by major employers. The real drama is in the net price, and honestly, net price is all that matters now.
Find detailed pricing trends and competitive breakdowns at RxInfo.ai. Spinraza’s story for 2025? More numbers than narrative. And Biogen, well, they’re on the clock.
